2014 Fiscal Year Final Research Report
New therapeutic target for human cholangiocarcinoma: systemic analysis of drug sensitivity and drug resistance for predicting the efficacy of adjuvant gemcitabine-based chemotherapy
| Project/Area Number |
24592028
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
上村 健一郎 広島大学, 医歯薬保健学研究院, 講師 (60379873)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 胆道癌 / 抗癌剤代謝関連酵素 / Gemcitabine / S1 / 個別化治療 |
|---|
| Outline of Final Research Achievements |
This study aims to assess hENT1 abundance and RRM1 expression in 127 patients with cholangiocarcinoma underwent adjuvant gemcitabine-based chemotherapy after resection. A RT-PCR and immunohistochemical assay were applied. Relationships between clinicopathologic factors, and disease-free and overall survival (DFS and OS) were evaluated.
High intratumoural hENT1 and RRM1 expression levels were observed in 86 (68%) and 67 (53%) patients by immunohistochemical assay. Linear correlation was observed between expression using immuhohistochemical assay and PCR assay (R=0.898; P<0.01). Concurrent high hENT1 and low RRM1 expression was a powerful independent predictor of prolonged DFS (P<0.001) and OS (P=0.001). We concluded that concurrent analysis of hENT1 and RRM1 expression may increase the predictive value of these biomarkers for survival of advanced cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
|
| Free Research Field |
肝胆膵外科
|
